BioMarin posted second-quarter revenue of $990 million, a 20% increase from the prior year. Management raised its 2026 revenue outlook by 65 basis points to a midpoint of $3.9 billion and adjusted earnings per share by 100 basis points to a midpoint of $5 per share. Shares rose nearly 4% on Aug. 7.
BioMarin's approved drugs have been granted orphan-drug status in the US and the EU, providing them with at least seven and 10 years of market exclusivity, respectively.
Diagnosis of very rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.29 | 12.57 | 9.33 |
Price/Book Value | 2.03 | 1.48 | 1.90 |
Price/Sales | 3.83 | 1.88 | 2.56 |
Price/Cash Flow | 14.22 | 7.77 | 10.58 |
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Quick Ratio | 1.16 | 0.49 | 0.85 |
Current Ratio | 2.39 | 0.99 | 1.27 |
Interest Coverage | 1.94 | 8.05 | 2.36 |
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.77% | 7.96% | 8.46% |
Return on Equity (Normalized) | 8.06% | 14.96% | 19.70% |
Return on Invested Capital (Normalized) | 6.64% | 11.28% | 12.66% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&&%&%@& | LOCK|XqYw | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^qxlYl | LOCK|wF@C< | $85B | |||
| argenx SE ADR
ARGX
| LOCK|c<v>^XS | LOCK|k&R | $65B | |||
| Moderna Inc
MRNA
| LOCK|G@Jbkv | LOCK|lfb | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|nS<%Vl | LOCK|PV | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gr?%%lm | LOCK|<&@n^ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Zmp@BSWc | LOCK|JzY# | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|^Hr?T< | LOCK|fb | $26B | |||
| Incyte Corp
INCY
| LOCK|QY$FK? | LOCK|ZB^ | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|XVl>h! | LOCK|S% | $16B |
United States